Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Not yet recruiting · NCT07811622 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Not applicable | 2026-09-10 | NCT07811622 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing Miracle Biotechnology Co., Ltd. | 3 |
| The First Affiliated Hospital of Nanchang University | 84 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Nanchang University | Nanchang | China | 77 |